Selective expression of α-synuclein-immunoreactivity in vesicular acetylcholine transporter-immunoreactive axons in the guinea pig rectum and human colon. by Sharrad, DF et al.
Archived at the Flinders Academic Commons: 
http://dspace.flinders.edu.au/dspace/ 
This is the peer reviewed version of the following article:  
Sharrad, D. F., de Vries, E. and Brookes, S. J.H. (2013), 
Selective expression of α-synuclein-immunoreactivity in 
vesicular acetylcholine transporter-immunoreactive 
axons in the guinea pig rectum and human colon. J. 
Comp. Neurol., 521: 657–676. 
which has been published in final form at 
doi:10.1002/cne.23198
 This article may be used for non-commercial purposes 
in accordance with Wiley Terms and Conditions for Self-
Archiving.
Sharrad et al Page 1 
Selective expression of α-synuclein-immunoreactivity in vesicular acetylcholine transporter-
immunoreactive axons in the guinea-pig rectum and human colon 
 
Dale F. Sharrad1, Elsbeth de Vries1 & Simon J.H. Brookes1 
 
1. Department of Human Physiology and Centre for Neuroscience, Flinders Medical Science and 
Technology, School of Medicine, Flinders University, Bedford Park, South Australia, Australia 
 
Abbreviated title: selective expression of α-synuclein in neurons to the gut 
 
Key words: Parkinson’s disease, enteric nervous system, cholinergic, Lewy pathology 
 
Corresponding author: Simon JH Brookes  
Department of Human Physiology  
Flinders University  
Bedford Park, SA, 5042, Australia 
Tel: +61 8 82044201 



























Sharrad et al Page 2 
Abstract  
  
Parkinson’s disease is a neurodegenerative disorder characterised by motor and non-motor 
impairments, including constipation. The hallmark pathological features of Parkinson’s disease are 
Lewy bodies and neurites, of which aggregated α-synuclein is a major constituent. Frequently, 
Lewy pathology is identified in the distal gut of constipated Parkinson’s disease patients. The 
neurons that innervate the distal gut that express α-synuclein have not been identified. We used 
multiple-labeling immunohistochemistry and anterograde tracing to quantify which neurons 
projecting to the guinea-pig rectum and human colon expressed α-synuclein in their axons. 
α-Synuclein-immunoreactivity was present in 24 ± 0.7% of somatostatin (SOM)-immunoreactive 
(IR) varicosities; 20 ± 4.3% of substance P (SP)-IR varicosities and 9 ± 1.3% vasoactive intestinal 
polypeptide (VIP)-IR varicosities in guinea-pig rectal myenteric ganglia. However, α-synuclein-
immunoreactivity was localised in significantly more vesicular acetylcholine transporter (VAChT)-
IR varicosities (88 ± 3%, p < 0.001). Of SOM-IR, SP-IR and VIP-IR varicosities that lacked 
VAChT-immunoreactivity, only 1 ± 0.3%, 0 ± 0.3% and 0% contained α-synuclein-
immunoreactivity, respectively. 71 ± 0.8% of VAChT-IR varicosities in myenteric ganglia of 
human colon were α-synuclein-IR. In guinea-pig rectal myenteric ganglia, α-synuclein- and 
VAChT-immunoreactivity co-existed in 15 ± 1.4% of biotinamide-labeled extrinsic varicosities; 
only 1 ± .3% of biotinamide-labeled extrinsic varicosities contained α-synuclein-immunoreactivity 
without VAChT-immunoreactivity. 
α-Synuclein expression in axons to the distal gut correlates closely with expression of the 
cholinergic marker, VAChT. This is the first report of cell-selective α-synuclein expression in the 
nervous system. Our results suggest cholinergic neurons in the gut may be vulnerable in 
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INTRODUCTION 
 
Parkinson’s disease is a neurodegenerative disorder that results in severe motor impairments caused 
by the death and dysfunction of dopaminergic neurons in the substantia nigra. The disease is also 
associated with loss of non-dopaminergic neurons throughout the nervous system and many non-
motor impairments, including insomnia, urinary incontinence and constipation (Halliday et al., 
1990; Zarow et al., 2003; Chaudhuri, Yates & Martinez-Martin, 2005). In the substantia nigra, 
surviving neurons often contain intracytoplasmic inclusion bodies, termed Lewy bodies, and 
dystrophic neurites, termed Lewy neurites. These abnormal protein aggregates are associated with 
cellular damage and are a characteristic feature of sporadic Parkinson’s disease (Jellinger, 1986). 
The major constituent of Lewy bodies and neurites is aggregated α-synuclein (Spillantini et al., 
1997). 
 
α-Synuclein is a neuronal protein of 140 amino acids localised to presynaptic terminals (Maroteaux, 
Campanelli & Scheller, 1988). Whether α-synuclein is expressed ubiquitously or selectively in 
presynaptic terminals throughout the nervous system has not been studied directly. Evidence for the 
function of α-synuclein is limited, but recent evidence suggests that it plays a role in maintaining 
SNARE-complex assembly in presynaptic terminals: a function that is particularly important in 
highly-active presynaptic terminals (Chandra et al., 2005; Burre et al., 2010). Abnormal forms of α-
synuclein are implicated in neurodegeneration in Parkinson’s disease. Mutations in SNCA, the gene 
encoding α-synuclein, including a base substitution (A53T) (Polymeropoulos et al., 1997), two 
point mutations (A30P and E46K) (Kruger et al., 1998; Zarranz et al., 2004), as well as gene 
duplications and triplications (Singleton et al., 2003; Nishioka et al., 2006), can cause Parkinson’s 
disease. Post-translational modifications to α-synuclein, including truncation (Liu et al., 2005), 
nitration (Giasson et al., 2000) and hyperphosphorylation (Anderson et al., 2006), are also 
implicated in the disease pathogenesis. Exposure to the pesticides, rotenone and paraquat, and the 
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toxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), have been identified as risk factors 
for Parkinson’s disease (Lai et al., 2002; Langston et al., 1983); in animal models, these agents 
induce aggregation of α-synuclein, formation of Lewy body-like inclusions and neurodegeneration 
(Betarbet et al., 2000; Fornai et al., 2005; Shults, 2004).  
 
Constipation is strongly associated with diagnosed Parkinson’s disease (Pfeiffer, 2003). When 
defined as fewer than three bowel movements per week, the frequency of Parkinson’s disease 
patients with constipation ranges from 20-89% (Edwards et al., 1991; Siddiqui et al., 2002; Kaye et 
al., 2006; Stocchi et al., 2000). Interestingly, constipation does not respond well to dopamine 
therapy (Chaudhuri, Healy & Schapira, 2006) and its onset may precede motor impairments (Abbott 
et al., 2001). The enteric nervous system is responsible for directly controlling gastrointestinal 
functions including motility, blood flow, and secretion (Furness & Costa, 1987). These functions 
are also regulated by sympathetic and parasympathetic neuronal inputs via modulation of enteric 
circuits (Wood, Alpers & Andrews, 1999). Damage to the innervation of the distal gut has been 
implicated in slow-transit constipation (Wattchow et al., 2008; Knowles, Scott & Luniss, 2001). 
Lewy pathology is frequently identified in the distal gut of constipated Parkinson’s disease patients 
(Lebouvier et al., 2008; Lebouvier et al., 2010a; Lebouvier et al., 2010b; Pouclet et al., 2011), 
potentially linking constipation with enteric neuropathology. 
 
The neurons in the gut that express α-synuclein have not been identified. The aim of our study was 
to identify which neurons to the guinea-pig rectum and human colon express α-synuclein in their 
axons. Enteric and extrinsic neurons can be distinguished on the basis of their ‘chemical coding’ 
(i.e. the combinations of neurotransmitters, neuropeptides and other molecules that they contain), 
and their axonal projections. Our findings indicate that α-synuclein expression is closely correlated 
with expression of the cholinergic marker, vesicular acetylcholine transporter.  
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MATERIALS AND METHODS 
Guinea-pig tissue collection and preparation 
 
Adult guinea pigs of either sex (weight 200–400g) were stunned and killed by exsanguination, in a 
manner approved by the Animal Welfare Committee of Flinders University, South Australia. The 
rectum with the attached mesentery and pelvic ganglia were removed, flushed free of contents, and 
placed in sterile Krebs solution (118 mM NaCl, 4.75 mM KCl, 1.0 mM NaH2PO4, 25 mM 
NaHCO3, 1.2 mM MgSO4, 11.1 mM D-glucose, 2.5 mM CaCl2, bubbled with 5% CO2 in 95% 
O2, pH 7.4). Tissue was pinned in a Sylgard-lined Petri dish (Dow Corning, Midland, MI) and 
pelvic ganglia were carefully dissected free from surrounding adipose tissue before the gut was 
opened longitudinally along side the rectal artery. The mucosa and submucosa were carefully 
removed and the remaining wholemount preparation was pinned serosal-side up, with the major 
pelvic ganglia secured loosely on either side. Krebs solution was regularly changed during 
dissection. The preparation was then either used for rapid anterograde tracing or detached from 
rectal nerves, maximally stretched and fixed overnight at 4°C in Zamboni’s fixative (2% 
formaldehyde, 15% saturated picric acid in 0.1M phosphate buffer, pH 7.0). Fixed preparations 
were cleared in DMSO (3 x 10 minutes) and rinsed in 0.1 M phosphate-buffered saline (PBS, 0.15 
M NaCl, pH 7.2).  
 
Patients and human tissue collection 
 
A total of 6 colon samples from 6 patients (4 male) were collected with prior written informed 
consent (Flinders Clinical Research Ethics Committee #388/09, valid 14/1/2010 – 14/1/2013) at 
Flinders Medical Centre or Flinders Private Hospital from  patients undergoing colonic resection for 
carcinoma (age range 26-70). The specimens used  were taken from macroscopically normal 
margins, and did not contain tumorous or inflamed tissue. None of the patients had experienced 
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colonic obstruction. Four samples were from descending colon; two were from sigmoid colon. 
Specimens were transported to the laboratory in oxygenated Krebs solution, dissected as described 
above and fixed in modified Zamboni’s fixative (2% paraformaldehyde, 0.2% saturated picric acid 
in 0.1M phosphate buffer; pH 7.2) for 48 hours. Preparations were then cleared and stored as 
described above. 
 
Rapid anterograde tracing  
 
Rectal nerve trunks were first positively identified by tracing back to the major pelvic ganglia, then 
detached and dissected free of connective tissue. The preparation (20-30mm in length) was then 
pinned in a partitioned Sylgard-lined dish. The nerve trunk ran under a glass coverslip and was 
pinned in a small Perspex isolation chamber sealed with high-vacuum silicon grease (Ajax, Auburn, 
NSW Australia). The nerve was washed in 3-4 changes of artificial intracellular medium solution 
(150 mM monopotassium, L-glutamic acid, 7 mM MgCl2, 5 mM glucose, 1 mM ethylene glycol-
bis-[β-aminoethyl ether] N,N,N’,N’-tetraacetic acid [EGTA], 20 mM hydroxyeicosapentaenoic acid 
[HEPES] buffer, 5 mM disodium adenosine-5-triphosphate [ATP], 0.02% saponin, 1% dimethyl 
sulphoxide [DMSO], 100 IU/ml penicillin, 100 µg/ml streptomycin, 20 µg/ml gentamycin sulphate; 
Tassicker et al., 1999), before the chamber was filled with paraffin oil. A small drop of 5% 
biotinamide (N-[2-aminoethyl] biotinamide, hydrobromide; Molecular Probes, Eugene, OR) 
dissolved in the same artificial intracellular solution was placed on the nerve. The Krebs solution in 
the main chamber was replaced with sterile culture medium and placed on a rocking tray in a 
humidified incubator at 37°C and in 5% CO2 in air. After 16 hours, preparations were maximally 
stretched and fixed and cleared as described above. Labeled fibers were visualized by incubating 
the preparations for 6 hours with streptavidin conjugated to Alexa-Fluor 488 (dilution 1:1000; 
Molecular Probes). 
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Immunohistochemistry 
 
Most of the circular and longitudinal muscle layers were removed from wholemount preparations to 
expose the myenteric plexus. They were then immersed for 1 hour in a blocking solution (20mg/mL 
bovine serum albumin, 5% normal donkey serum, 95% PBS Triton-X (PBS Triton-X: 99.5% PBS, 
0.5% Triton-X) to reduce background labeling, then incubated with antibodies against different 
neurotransmitter-related markers (Table 1) for 16–72 hours at room temperature, rinsed with PBS, 
and incubated with appropriate secondary antibodies (Table 2) for 2–4 hours. After a final rinse 
with PBS, preparations were equilibrated with 50, 70, and 100% carbonate-buffered glycerol, and 
mounted in 100% carbonate-buffered glycerol (pH 8.6). All antibodies were diluted in 0.1 M PBS 




α-Synuclein: Two polyclonal antibodies against α-synuclein raised in sheep and rabbit were used: 
they gave identical labeling. The rabbit polyclonal antibody (Rb2-190303-WS), generously 
provided by Dr. WP Gai of Flinders University, recognizes a 19 kDA band on Western blots of 
human cerebral cortex extracts at the molecular weight of α-synuclein and does not cross-react with 
β-synuclein. Staining was abolished after incubation with 20μg/ml of the cognate peptide (Jakes, 
Spillantini & Goedert, 1994). The sheep polyclonal antibody against α-synuclein was generously 
provided by Dr. WP Gai of Flinders University. Staining with this antibody is abolished by pre-
absorption with the immunizing antigen and recombinant human α-synuclein (Gai et al. 1999).  The 
sheep antiserum gave identical labeling, to the level of single varicosities, when double-labeled with 
the rabbit antiserum in the present study (n=4).   
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5-hydroxytryptamine: Staining with this antibody (Incstar; Cat. No. 20079; Lot No. 108072) was 
abolished by incubation of the diluted antibody with 100 μg of 5-HT/BSA conjugate 
(manufacturer’s data sheet).  
Calbindin: The calbindin antibody (SWANT; Cat. No. CB38; Lot No. 5.5) was a polyclonal raised 
in rabbit against recombinant rat calbindin D-28k. In Western blots, it recognizes a single band of 
approximately 27-28 kDA of mouse brain, corresponding to the protein’s molecular weight 
(manufacturer’s datasheet; Ng et al., 1996). The antibody does not stain the brain of calbindin D-
28k knockout mice (manufacturer’s datasheet). Staining is abolished by pre-absorption with 1μM of 
recombinant rat calbindin D-28k (Reiche et al., 1999). 
Calretinin: The calretinin antibody (Rogers, Cat. No. Ab-6C), generously provided by Dr. JH 
Rogers of Cambridge University, was a polyclonal raised in chick against calretinin-β-galactosidase 
fusion protein, containing putative calcium binding domains III and IV (Rogers, 1989a&b). The 
antibody stains a single 29 kDa band in rat cerebellum homogenates on Western blots (Bell, Meek 
& Yang, 2005), corresponding to the protein’s molecular weight (Rogers, 1989b). 
Calcitonin gene-related peptide: The calcitonin gene-related peptide (CGRP) antibody (Peninsula; 
Cat. No. IHC6006; Lot. No. 040826-2) was a polyclonal raised in rabbit against rat CGRP (peptide 
sequence: HSCATATCVTHRLAGLLSRSGGVVKNNFVPTNVGSEAF-NH2). It recognized a 
single band of approximately 14 kDa, corresponding to CGRP’s molecular weight, on western blots 
of horse ileum homogenates (Russo et al., 2010). Pre-absorption of the diluted antibody with the 
immunogen abolishes staining in horse spinal cord, dorsal root ganglia, and intestine (Domeneghini 
et al., 2004).  
Choline acetyltransferase: The choline acetyltransferase (ChAT) antibody, (Schemann; Cat. No. 
P3YEB), generously provided by Dr. M Schemann of Technische Universitat Muenchen, was 
raised in rabbit against a 22 amino acid peptide fragment of purified porcine ChAT (peptide 
sequence: GLFSSYRLPGHTQDTLVAQKSS). It labels a single band on western blots of guinea-
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pig inferior mesenteric ganglion and pelvic ganglia of 65 kDa, compared with the ChAT theoretical 
molecular weight of 72 kDa (Olsson et al., 2006). 
Neuronal nitric oxide synthase: The neuronal nitric oxide synthase (nNOS) antibody (Emson; Cat. 
No. K205), generously provided by Dr. P Emson, was a polyclonal raised in sheep against 
recombinant rat brain nNOS. It labels an intense band at 160 kDa (theoretical molecular weight of 
160 kDa) and a fainter band at 40 kDA on western blots of guinea-pig inferior mesenteric ganglion 
and pelvic ganglia (Olsson et al., 2006).  
Substance P: The substance P (SP) antibody (Chemicon; Cat. No. MAB356; Lot No. LV1362790) 
was a monoclonal raised in rats against substance P conjugated to bovine serum albumin with 
carbodiimide (Cuello, Glafre & Milstein, 1979). The specificity of the antibody for SP has been 
validated by radioimmunoassay (Hegarty et al., 2010). Pre-absorption of the antibody with 
200μg/ml of the SP peptide abolishes labeling (Cuello, Glafre & Milstein, 1979).  
Somatostatin: The somatostatin antibody, (Brown; Cat. No. Soma 8), was a monoclonal raised in 
mice against somatostatin-14 conjugated to keyhole limpet hemocyanin using carbodiimide 
(Buchan et al., 1985). Pre-absorption of the diluted antibody with 100μg/ml somatostatin-14 
abolished labeling in the rat amygdala (Muller, Mascagni & McDonald, 2007).  
Tyrosine hydroxylase: The TH antibody, (Diasorin; Cat. No. 22941; Lot. No. 136032), was a 
mouse monoclonal raised against TH extracted from rat PC12 cells. The antibody labels an intense 
band of 60 kDa (theoretical molecular weight of 56 kDa) and a faint band of 52-54 kDa in western 
blots of guinea-pig inferior mesenteric ganglion and pelvic ganglia (Olsson et al., 2006).  
VIP: The polyclonal VIP antibody (Chemicon; Cat. No. AB1581, Lot No. 0611044826) was raised 
in sheep against synthetic peptide VIP (1-28) coupled to keyhole limpet hemocyanin with 
glutaraldehyde. The monoclonal VIP antibody (Murphy; Cat. No. F1/1II), generously provided by 
Dr. R Murphy, was raised in rats against porcine VIP coupled to thyroglobulin using carbodiimide. 
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When used in double-labeling immunohistochemical protocol, the two antibodies revealed identical 
labeling profiles.  
Vesicular acetylcholine transporter: The goat polyclonal antibody, (Phoenix Pharmaceuticals; 
Cat. No. HV007; Lot No. 417149), was a polyclonal raised in goat against the C-terminal of human 
VAChT (peptide sequence: CTRSRSERDVLLDEPPGLYDAVRLRE). Pre-absorption of the 
antibody with 50μm of the immunogen abolished labeling in the dentate gyrus of monkeys (Shamy 
et al., 2007). The rabbit polyclonal antibody was raised against the same synthetic peptide sequence 
of rat VAChT (peptide sequence: CTRSRSERDVLLDEPPQGLYDAVRLRE) conjugated to blue 
carrier protein. In double-labeling immunohistochemical investigations, the two antibodies against 
VAChT had identical labeling profiles.  
 
Microscopy and image analysis 
Labeled nerves were examined on an Olympus IX71 microscope (Japan) equipped with 
epifluorescence and highly discriminating filters (Chroma Technology Co., Battledore, VT). Images 
were captured using a Roper scientific (Coolsnap) camera using AnalySIS Imager 5.0 (Olympus-
SIS, Münster, Germany) and saved as TIFF files. Matched micrographs of immunohistochemically- 
and biotinamide-labeled nerve structures were captured using a 40x objective water-immersion lens 
and displayed in ImageJ (NIH, Bethesda, MD) as a stack. By rapidly switching between matched 
micrographs, it was possible to determine accurately whether a single, randomly chosen, labeled 
varicosity contained one or more particular markers (Olsson et al. 2004). Varicosities were selected 
by moving the mouse cursor rapidly to a region of the ganglion that had not yet been sampled.  
Wherever the cursor stopped, the closest in-focus usable varicosity to the cursor was selected, 
irrespective of size or intensity of labelling. This method will be referred to as the “cursor-selected 
coordinate” method. Varicosities that were out-of-focus or overlying intensely labeled nerve cell 
bodies or other structures were excluded. Five or ten varicosities were selected at widely separated 
sites in each ganglion and either 20 or 10 stacks were examined, giving total counts of 100 
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varicosities, in each of four guinea-pig or six human specimens. For biotinamide-labeled axons, the 
“cursor-selected coordinate” method was used to select five varicosities in a myenteric ganglion 
from each of 20 stacks, leading to total counts of 100 varicosities per combination (n=8). To 
analyse axons in the muscle layers of guinea pig colorectum, a transect line was drawn diagonally 
across the stack and the 5 varicosities closest to the line were quantified from 20 stacks, resulting in 
total counts of 100 varicosities in each of the four animals. On some preparations, varicosities in 
myenteric ganglia from guinea-pig rectum were re-analysed using a different “fixed coordinate 
sampling” method. A transparent overlay was marked with with 50 unevenly spaced, numbered 
coordinates and placed over the computer monitor. The 10 coordinates with the lowest numbers that 
lay within the ganglion outline were selected. The nearest varicosity that was in focus to each  
coordinates were then selected and tested for co-existence as described above. Out-of-focus 
varicosities and those lying above intensely labelled cell bodies were excluded, but varicosity size 
and intensity of labelling were not taken into account.. Again, 10 stacks were examined this way, 
giving total counts of 100 varicosities, in each of four guinea-pig specimens. Group data are 
expressed as percentage means (mean number of varicosities from a sample of 100 for all guinea-
pig data and mean number of varicosities from a sample of 50 for all human data) ± standard error 
of the mean (SEM), with n referring to the number of animals or patients.  
 
Additionally, some preparations were examined on a Leica TCS SP5 confocal laser-scanning 
microscope (Leica Microsystems, Wetzlar, Germany) with a 63x objective oil lens at 1x digital 
zoom. Scan area was set to 1024x1024 pixels and the scan speed was set to 400Hz. With the 
pinhole set to 1 AU, Z-series images were acquired at 0.5µM z-steps, with two line averages, 
through myenteric ganglia. Using sequential scans, matched Z-series of myenteric ganglia, labeled 
with two markers, were imaged. Images were captured as .lif files and exported as TIFF files for 
image analysis as stacks. Co-existence of markers in varicosities was tested in 5 varicosities in four 
matched optical slices separated by at least 2.5µm in the Z-axis using the “cursor-selected 
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coordinate” method. Thus, 20 varicosities were sampled per ganglion. A total of five myenteric 
ganglia were sampled per preparation, leading to total counts of 100 varicosities (n=3). Group data 
are expressed as percentage means ± SEM.  
 
One-way ANOVA with Tukey’s HSD Test in SPSS19 for PC (SPSS, Chicago, IL) was used to 
compare the means of more than two samples. The means of two samples were compared by a 
Student’s unpaired t-test in Microsoft Excel 2008 for Mac (Microsoft, Santa Rosa, CA). Pearson’s 
Chi-squared goodness-of-fit test was performed to compare the observed and expected frequency 
distributions in a population in Microsoft Excel 2008 for Mac. Differences were considered 
significant at P < 0.05. Fluorescence and confocal micrographs were prepared with Adobe 
Photoshop CS5. Figures were generated from grayscale images adjusted for contrast and brightness 
and were cropped and resized to improve display of varicosities of interest.  
 
RESULTS 
The rectum was defined as the region of distal gut that receives rectal nerves arising from pelvic 
ganglia (the most distal 6-8 cm; Olsson et al. 2004 & 2006). In most cases, analysis was 
concentrated on varicosities in myenteric ganglia although where indicated, axons in the tertiary 
plexus or deep muscular plexus were examined. 
Reliability of antisera used to label varicosities 
Preparations of guinea pig rectum double-labeled with two antisera to α-synuclein revealed nearly 
complete co-existence of immunoreactivity in varicosities (sheep α-synuclein+/rabbit α-synuclein+: 
100 ± 0% and rabbit α-synuclein+/sheep α-synuclein+: 100 ± 0.3%, n=4) (Fig. 1). In preparations 
of guinea-pig rectum, two different antisera against vesicular acetylcholine transporter (VAChT) 
showed a high-degree of co-existence (goat VAChT+/rabbit VAChT+: 99 ± 0.7% and rabbit 
VAChT+/goat VAChT+: 100 ± 0%, n=4) (Fig. 1). Co-existence of choline acetyltransferase 
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(ChAT) and VAChT was also quantified on preparations of circular muscle from guinea-pig ileum. 
The high degree of overlap (ChAT+/VAChT+: 85 ± 1.3% and VAChT+/ChAT+: 86 ± 2%, n=4) 
(Fig. 1) suggested that VAChT and ChAT were reliable markers for cholinergic varicosities in the 
gut wall.  
α-Synuclein-immunoreactive nerve structures in the gut 
α-Synuclein-immunoreactivity was present in numerous axonal varicosities in myenteric ganglia, 
tertiary plexus, internodal strands and deep muscular plexus (Fig. 2) (Phillips et al. 2008), but was 
not visible in nerve cell bodies, glial cells, smooth muscle cells, or interstitial cells of Cajal. 
Immunoreactivity was present in red blood cells, but this was readily distinguishable from axonal 
varicosities and was not studied further.  
Populations of neurotransmitter-related varicosities immunoreactive for α-synuclein in the 
gut 
Myenteric plexus of guinea-pig rectum 
Myenteric neurons and their axons in guinea-pig distal bowel belong to 12-15 classes 
distinguishable by immunohistochemical markers (Lomax & Furness 2000). The proportion of each 
class of axon that contained α-synuclein was quantified (Fig. 3, Table 3). There were significant 
differences in these proportions between classes.  For example, 11 ± 0.9% (n=4) of varicosities 
immunoreactive for 5-hydroxytryptamine (5-HT) were immunoreactive for α-synuclein, compared 
to 24 ± 2.8% (n=4) of varicosities immunoreactive for substance P (SP; P < 0.005, f = 139.1, df = 
9). Similarly, a greater proportion of varicosities immunoreactive for somatostatin (SOM; 26 ± 
3.1%, n=4) contained α-synuclein-immunoreactivity compared to varicosities immunoreactive for 
nitric oxide synthase (NOS; 12 ± 1.1%, n=4) (P < 0.001). Consistently, more VAChT-containing 
varicosities were immunoreactive for α-synuclein than any other class (86 ± 1.8%, n=4; P < 0.001 
in all cases).  
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Myenteric plexus of human colon 
The same method of analysis was applied to classes of varicosities in myenteric ganglia from 
human colon (Table 3, Fig. 4). On average, 11 ± 1.1% of VIP-immunoreactive varicosities were 
immunoreactive for α-synuclein and 9 ± 0.9% of 5-HT-IR varicosities were immunoreactive for α-
synuclein (n=6). More VAChT-IR varicosities were immunoreactive for α-synuclein (78 ± 0.8%, 6 
human specimens) than any of the other neurotransmitter-defined classes studied (P < 0.001, f = 
541.7, df = 4). 
Deep muscular plexus and tertiary plexus of guinea-pig rectum 
There were also significant differences in the co-existence of α-synuclein with neurotransmitter-
related markers in the deep muscular plexus and tertiary plexus in the guinea-pig rectum (Fig. 5). In 
the deep muscular plexus, more VAChT-IR varicosities contained α-synuclein (98 ± 0.6%, n=4), 
than NOS-IR varicosities (2 ± 0.6%, n=4; P < 0.001, t = -107.9, df = 6). Likewise, the proportion of 
VAChT-IR varicosities that contained α-synuclein-immunoreactivity (99 ± 0.7%, n=4) in the 
tertiary plexus was significantly greater than the proportion of NOS-IR varicosities (1 ± 0.4%, n=4) 
(P < 0.001, t = -127.7, df = 6). 
Submucous plexus of guinea-pig rectum 
Submucousal neurons and their axons in guinea-pig distal bowel belong to 4 classes, 
distinguishable by immunoreactivity for ChAT or VIP in combination with additional 
immunohistochemical markers (Lomax & Furness 2000). Similar to the myenteric plexus, a 
significantly greater proportion of VAChT-IR varicosities contained α-synuclein-immunoreactivity 
than any other markers (SOM, VIP and TH) studied (Fig. 6; 68 ± 3.6%, n=4, Table 4) (P < 0.001, f 
= 175.3, df = 3). 
Populations to which the α-synuclein-immunoreactive varicosities belong to in the gut 
Myenteric plexus of guinea-pig rectum 
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The co-existence of axonal markers with α-synuclein was also counted the other way round, i.e. the 
proportion of all α-synuclein varicosities that contained specific markers was counted (Table 5). For 
example, 5-HT-IR varicosities comprised 6 ± 1.1% (n=4) of all α-synuclein-immunoreactive 
varicosities, whereas SP-immunoreactivity was detectable in 16 ± 3.7% (n=4). A significantly 
greater proportion of α-synuclein-IR varicosities contained VAChT-immunoreactivity than any 
other marker  (88 ± 3%, n=4) (P < 0.001 in all cases, f = 165.1, df = 9).  
Myenteric plexus of human colon 
In myenteric ganglia from human colon, a significantly greater proportion of α-synuclein-IR 
varicosities contained VAChT-immunoreactivity than any other marker (71 ± 0.9%, n=6, Table 5) 
(P < 0.001 in all cases, f = 620.7, df = 4; see Table 4). 
Deep muscular plexus and tertiary plexus of guinea-pig rectum 
In the deep muscular plexus of guinea pig rectum, all α-synuclein-IR varicosities appeared to 
contain VAChT-immunoreactivity (100 ± 0.3%, n=4) whereas NOS-immunoreactivity was almost 
absent (0 ± 0.3%, n=4) (P < .001, t = -259.9, df = 6). Similarly, in the tertiary plexus, more α-
synuclein-IR varicosities contained VAChT-immunoreactivity (99 ± 0.3%, n=4) than NOS-
immunoreactivity (1 ± 0.3%, n=4) (P < 0.001, t = -278.6, df = 6).  
Submucous plexus of guinea-pig rectum 
Similarly, in the submucous plexus, a significantly greater proportion of α-synuclein-IR varicosities 
contained VAChT-immunoreactivity than any of the other markers (SOM, VIP and TH) studied (65 
± 3.4%, n-4, Table 6) (P < 0.001 in all cases, f = 232.7, df = 3).  
Co-existence of VAChT-immunoreactivity with axonal markers 
Many cholinergic neurons in myenteric ganglia of guinea-pig distal gut contain other markers, 
including 5-HT, SP, SOM and VIP (Lomax & Furness 2000). To determine whether co-existence 
with VAChT could account for the subset of each of these classes that contained α-synuclein-
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immunoreactivity, preparations were double-labeled with antisera against VAChT and one other 
marker. The proportion of VAChT-immunoreactivity in varicosities of different classes varied 
widely (Table 3). Of NOS-IR varicosities, 5 ± 0.3% (n=4) contained VAChT-immunoreactivity, 
compared to 29 ± 4.1% (n=4) of SOM-IR varicosities. Strikingly, the proportion of VAChT-IR 
varicosities in each population was similar to the proportion containing α-synuclein-IR. For 
example, 26 ± 3.1% (n=4) of SOM-IR varicosities were immunoreactive for α-synuclein and 29 ± 
4.1% (n=4) of SOM-IR varicosities were immunoreactive for VAChT. This is shown in a 
scatterplot of the proportion of α-synuclein-IR varicosities in a population against the mean 
proportion of VAChT-IR varicosities in the same population (Fig. 7). Together, the results suggest 
α-synuclein and VAChT probably co-exist with neurotransmitter-related markers in varicosities. 
Co-existence of VAChT and α-synuclein-immunoreactivity with other markers 
The co-existence of α-synuclein and VAChT in SOM-, SP- and VIP-IR varicosities was tested 
directly using triple-labeling immunohistochemistry (Fig. 8). Of SOM-IR varicosities, 24 ± 0.7% 
(n=4) were immunoreactive for both VAChT and α-synuclein. Only 1 ± 0.3% (n=4) of SOM 
varicosities contained α-synuclein without VAChT-immunoreactivity, and just 1 ± 0.3% (n=4) of 
SOM varicosities with VAChT lacked α-synuclein-immunoreactivity. Thus, α-synuclein- and 
VAChT-immunoreactivity almost always co-existed in SOM-IR varicosities, which was 
significantly non-random (P < 0.001). A comparable high degree of α-synuclein and VAChT co-
existence was also observed in SP-IR and VIP-IR populations of varicosities (Fig. 9). 
Co-existence of VAChT-immmunoreactivity and α-synuclein-immunoreactivity in 
biotinamide-labeled extrinsic axons in guinea-pig rectum 
Rectal nerves contain axons of sacral parasympathetic efferent neurons that are VAChT-IR (Olsson 
et al. 2004 & 2006). Parasympathetic efferents and sympathetic efferents can be distinguished by 
VAChT- and TH-immunoreactivity, respectively (Olsson et al. 2004 & 2006). CGRP-
immunoreactivity distinguishes many spinal afferents from both sympathetic and parasympathetic 
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efferents (Domoto et al., 1992; Keast & de Groat, 1992). In extrinsic axons anterogradely labeled 
from rectal nerve trunks with biotinamide (Fig. 10), 15 ± 1.4% (n=8) were immunoreactive for both 
α-synuclein and VAChT. Only 1 ± 0.3% (n=8) of biotinamide-labeled varicosities immunoreactive 
for α-synuclein lacked VAChT-immunoreactivity, and just 3 ± 0.6% (n=8) of biotinamide-labeled 
varicosities immunoreactive for VAChT lacked α-synuclein-immunoreactivity. Again this 
coexistence of VAChT and α-synuclein was non-random (P < 0.001). 
Comparison of fluorescence and confocal microscope analysis 
Epifluorescence microscopy is an efficient technique for estimating the co-existence of markers 
within large numbers of varicosities from multiple preparations, but is limited by spatial resolution, 
particularly in the z-axis. To test whether this was likely to confound our data, co-existence was 
analyzed in single optical sections (approximately 0.5μm in thickness) from confocal micrographs 
(Fig. 11). Paired sections were compared in ImageJ. The results were closely comparable to those 
from epifluorescence microscopy (Table 5). For example, 18 ± 2% (n=3) of VIP-IR varicosities 
contained α-synuclein-immunoreactivity on fluorescence micrographs, compared to 16 ± 0.7% 
(n=3) in the same preparations in confocal micrographs. 
 
Comparison of fixed coordinate and cursor-selected coordinate sampling methodology 
Throughout this study, we routinely used the “cursor-selected coordinate” sampling method to 
select varicosities. To test the validity of this method, we used a “fixed-coordinate sampling” 
method that involved selecting varicosities closest to fixed, randomly generated sites on the screen, 
thus eliminating selection bias that may have inadvertently been introduced by the “cursor-selected 
coordinate” sampling method. The results were closely comparable between the two methods 
(Table 8). For example, 91 ± 1% (n=4) of VAChT-IR varicosities contained α-synuclein-
immunoreactivity when analyzed using the fixed-coordinate sampling method, compared to 88 ± 
2.6% (n=4) in the same preparations when using the cursor-selected coordinate sampling method.   
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DISCUSSION 
 
Enteric neurons, mostly in the myenteric plexus, control intestinal motility. They release many 
neurotransmitters, including small molecules such as acetylcholine, adenosine-5’-triphosphate, 5-
hydroxytryptamine and nitric oxide, as well as neuropeptides, including somatostatin, substance P, 
and vasoactive intestinal polypeptide (Furness et al., 1992; Galligan et al., 2000). Many of these 
transmitters, or associated enzymes have been used as immunohistochemical markers of cell bodies 
that distinguish different functional classes of enteric neurons (Costa et al., 1996). Many of these 
markers are also localized in axonal varicosities, and can therefore distinguish functional classes of 
axons too. In this study we used these markers to identify which enteric neurons express α-
synuclein, a protein which is largely restricted to axons.  
 
α-Synuclein is selectively expressed in the nervous system 
 
In the distal gut, the present study has shown that α-synuclein is expressed in the majority of 
cholinergic enteric axons that express vesicular acetylcholine transporter (VAChT) in their axons, 
but was much less abundant in axons that expressed other transmitters without VAChT. Several 
lines of evidence supported this finding. First, there was a significant correlation between VAChT 
and α-synuclein expression across many classes of enteric neurons in the guinea-pig distal gut (Fig. 
8). Second, immunohistochemical triple-labeling confirmed this finding in enteric neurons 
containing three peptides: SP, VIP and SOM. Similar results were obtained from a more limited 
study of human colon, where co-existence of α-synuclein with VAChT was significantly higher 
than with 5-HT, CGRP, NOS, TH and VIP. Similarly, α-synuclein in extrinsic pathways to the 
guinea-pig distal gut was more strongly associated with parasympathetic cholinergic axons 
(identified by VAChT-immunoreactivity) than peptidergic spinal afferent or tyrosine-hydroxylase-
containing sympathetic axons.   
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Studies elsewhere in the nervous system also suggest that α-synuclein is differentially expressed in 
various brain regions. In-situ hybridization in the human central nervous system did not detect α-
synuclein in the lateral and medial globus pallidus, dorsal medial nucleus or subthalamic nucleus, 
superior colliculus, red nucleus or periaqueductal gray (Solano et al., 2000). In the rat central 
nervous system, α-synuclein expression was not detectable by in-situ hybridisation in either the 
thalamus or hypothalamus (Maroteaux & Scheller, 1991). Immunoreactivity for α-synuclein was 
reported to be undetectable in the neuropil of the human habenular nucleus (Braak et al., 2000), rat 
habenular nucleus (Li, Henning-Jensen & Dahlstrom, 2002), and vagal afferent terminals in the rat 
gastric myenteric plexus (Phillips et al., 2008). These results suggest, in agreement with the present 
study, that α-synuclein is not ubiquitously expressed by all nerve cells, but is abundant in some and 
undetectable in others. 
 
α-Synuclein expression has been reported previously in cholinergic neurons. It is expressed in the 
caudate and putamen (Solano et al., 2000), the pedunculopontine tegmental nucleus (Maroteaux & 
Scheller, 1991) and the nucleus basalis of Meynert (Solano et al. 2000). It is also expressed in the 
terminals of vagal parasympathetic efferent neurons in the rat stomach (Phillips et al. 2008). Of 
course, α-synuclein expression is not limited to cholinergic neurons; it is also expressed in 
numerous non-cholinergic nuclei throughout the central nervous system, including the substantia 
nigra, locus coeruleus, hippocampus, and nucleus accumbens (Solano et al., 2000).  
 
Significance of α-synuclein expression in particular classes of neurons 
 
Expression of α-synuclein in specific classes of neurons is clearly not restricted to any particular 
neurotransmitter. In the gut, acetylcholine, acting at nicotinic receptors, is the primary mediator of 
fast synaptic transmission (Galligan et al., 2000); amino acids, such as glutamate, play a much 
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smaller role than in the central nervous system. Like excitatory amino acids, acetylcholine is 
released from small synaptic vesicles, rather than the large dense-core vesicles associated with 
peptides (Weihe et al., 1996). However, α-synuclein is probably not associated specifically with all 
small clear vesicles. In enteric inhibitory motor neurons, which release both peptides and ATP, 
there are peptidergic, large dense-core vesicles and small clear synaptic vesicles (Llewellyn-Smith 
et al., 1988). These neurons have been shown to consistently lack α-synuclein-immunoreactivity in 
the present study.  
 
Throughout the nervous system, α-synuclein is concentrated in axons rather than dendrites or nerve 
cell bodies. It appears to play a role related to the release and recycling of synaptic vesicles in 
presynaptic terminals. During release of fast neurotransmitters from synaptic vesicles, rapid 
assembly and disassembly of multiple SNARE-complexes is required (Montecucco, Schiavo & 
Pantano, 2005; Mohrmann et al., 2010). Depending on the synapse, from 1 to 300 small synaptic 
vesicles can be released in synchrony with a single action potential (Nicholls et al., 2001). This 
process can occur up to 100 times per second (Kushmerick, Renden & von Gersdorff, 2006). 
SNARE-complex cycling can generate short-lived, but highly reactive unfolded SNARE protein 
intermediates. Under some circumstances, these can form toxic aggregates, which may or may not 
be degraded; such aggregates may lead to neurodegenerative changes (Sharma, Burre & Sudhof, 
2011). During synaptic activity, α-synuclein chaperones the SNARE protein, synaptobrevin-2 
(Burre et al., 2010), protecting it from damage and ensuring that the presynaptic terminal is capable 
of maintaining SNARE-complex assembly (Burre et al., 2010; Sharma, Burre & Sudhof, 2011; 
Sharma et al., 2011). α-Synuclein acts in combination with other synucleins (β- and γ-synuclein) 
and cysteine-string protein-α (CSP-α), which likewise assist in maintaining the levels of functional 
SNARE proteins (Chandra et al., 2004 & 2005; Cabin et al., 2002). It is possible that the selective 
expression of α-synuclein in cholinergic enteric neurons may be related to their need for rapid 
turnover of this major fast transmitter and the associated requirement to chaperone SNARE proteins 
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adequately. Consistent with this, many synaptic vesicle proteins and SNARE proteins have been 
localized in the enteric nervous system of guinea pig (Vanden Berghe & Klingauf, 2007) and 
human (Nirasawa et al., 2001), particularly in cholinergic axonal varicosities (Harrington et al., 
2010). In contrast, some peptidergic sensory neurons lack all three vesicular glutamate transporters 
and therefore probably do not release a fast neurotransmitter (Morris et al., 2005). These neurons 
also lack synaptic vesicle proteins and SNARE proteins (Morris et al., 2005) and have been shown 
in the present study to lack α-synuclein. In addition, other variables could contribute to selective 
expression of α-synuclein. Previously, differential expression patterns of α-synuclein in nitrergic 
and cholinergic enteric neurons have been reported in the fundus and corpus of the rat myenteric 
plexus (Phillips et al. 2008). These findings suggest that region-dependent functions, or interspecies 
differences, may also influence α-synuclein expression in the nervous system.  
 
Vulnerability of cholinergic neurons in the gut in Parkinson’s disease 
 
In Parkinson’s disease, we speculate that cholinergic neurons may be particularly susceptible to 
degeneration. Age-related loss of neurons is more extensive in cholinergic enteric neurons than in 
nitrergic neurons (Bernard et al., 2009). This may be significant in Parkinson’s disease, where 
Lewy pathology is frequently identified in the distal gut of constipated patients recently diagnosed 
with Parkinson’s disease, but is absent from the distal gut of normal age-matched controls 
(Lebouvier et al., 2008; Lebouvier et al., 2010b; Pouclet et al., 2011). If Lewy pathology targets 
cholinergic enteric and parasympathetic neurons in the distal bowel, this could contribute to the 
etiology of Parkinson’s disease-related constipation. Cholinergic parasympathetic neurons to the 
rectum originate in the sacral parasympathetic nucleus of the spinal cord and pelvic plexus ganglia 
(Bessant & Robertson-Rintoul, 1986; Olsson et al., 2006): regions which often display Lewy 
pathology in Parkinson’s disease (Beach et al., 2009; Wakabayashi & Takahashi, 1997), even 
before the onset of motor impairments (Bloch et al., 2006). Selective damage to sacral 
parasympathetic pathways would also be expected to contribute to constipation. One interesting 
possibility that arises from these observations is that Lewy pathology in biopsies of human colon 
could be an early predictor of developing Parkinson’s disease (Lebouvier et al. 2010a). It remains to 
be determined whether Lewy pathology specifically targets cholinergic enteric and parasympathetic 
neurons in the bowel of patients with Parkinson’s disease. 
In summary, we report that α-synuclein is expressed selectively in particular classes of neurons in 
one component of the nervous system: the enteric nervous system. Selective expression of α-
synuclein may also occur in other regions of the nervous system and could be investigated using 
similar immunohistochemical techniques. Regional variations in the expression of α-synuclein may 
contribute to selective neuronal vulnerability in Parkinson’s disease. In addition, preparations of gut 
tissue may be a useful additional model to study selective neurodegeneration and characterise α-
synuclein function. 
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Figure 1. Paired fluorescence images of nerve structures in the guinea-pig rectum 
immunohistochemically double-labeled with two separate antisera to either VAChT, α-synuclein or 
ChAT. A & B: The pattern of labeling with antisera raised in rabbit (R - α-Syn) and sheep (S - α-
Syn) against α-synuclein was identical. C & D: Preparations double-labeled with VAChT antisera 
raised in rabbit (R - VAChT) and goat (G - VAChT) also showed identical patterns of labeling. E & 
F: The pattern of labeling with antisera against ChAT and VAChT was very similar. This suggested 
that the antisera against VAChT, α-synuclein and ChAT could be used interchangeably. Scale bar = 
20 μm. Abbreviations: α-Syn, α-synuclein; ChAT, choline acetyltransferase; G, goat; R, rabbit; 
VAChT, vesicular acetylcholine transporter.  
 
Figure 2. Fluorescence images of α-synuclein-IR nerve structures in the guinea-pig rectum (A, C & 
E) and human colon (B, D & F). A & B: α-Synuclein-immunoreactivity is present in myenteric 
ganglia (indicated by stars), internodal strands (indicated by arrows) and varicose axons that leave 
ganglia and enter the the muscle layers (indicated by arrow heads). Varicose axons innervating the 
longitudinal muscle (C & D) and circular muscle (E & F) are α-synuclein-IR.  The lack of 
sharpness of varicosities in thick wholemounts of human colonic muscle precluded quantitative 
analysis of co-existence within these populations of putative motor neurons. Scale bars = 20 μm. 
Abbreviations: -IR, immunoreactive.          
 
Figure 3. Paired fluorescence images of guinea-pig rectal myenteric ganglia 
immunohistochemically double-labeled with antisera against α-synuclein and either 5-HT (A & B), 
NOS (C & D) or VAChT (E & F). Varicosities that contained immunoreactivity for α-synuclein 
and the other marker are indicated by arrows, and varicosities immunoreactive for either α-
synuclein or the other marker alone are indicated by arrowheads. Scale bars = 20 μm. 
Abbreviations: 5-HT, 5-hydroxytryptamine; NOS, nitric oxide synthase; VAChT, vesicular 
acetylcholine transporter.  
 
Figure 4. Paired fluorescence images of myenteric ganglia from human colon 
immunohistochemically double-labeled with antisera against α-synuclein and either 5-HT (A & B), 
TH (C & D) or VAChT (E & F). Varicosities that contained immunoreactivity for α-synuclein and 
the other marker are indicated by arrows, and varicosities immunoreactive for either α-synuclein or 
the other marker alone are indicated by arrowheads. Scale bars = 20 μm. Abbreviations: 5-HT, 5-
hydroxytryptamine; TH, tyrosine hydroxylase; VAChT, vesicular acetylcholine transporter. 
 
Figure 5. Paired fluorescence images of varicose axons in the deep muscular plexus (A-D) and 
tertiary plexus (E-H) of the guinea-pig rectum immunohistochemically double-labeled with antisera 
against α-synuclein and either NOS or VAChT. Immunoreactivity for α-synuclein and VAChT co-
existed in nearly all varicosities (indicated by arrows) in the deep muscular plexus (A & B) and 
tertiary plexus (E & F). Immunoreactivity for NOS and α-synuclein rarely co-existed in varicosities 
(indicated by arrowheads), suggesting antisera against NOS and α-synuclein label two distinct 
populations of varicose axons in the deep muscular plexus (C & D) and tertiary plexus (G & H). 
Scale bars = 20 μm. Abbreviations: NOS, nitric oxide synthase; VAChT, vesicular acetylcholine 
transporter. 
 
Figure 6.  Paired fluorescence images of submucousal ganglia from guinea-pig rectum 
immunohistochemically double-labeled with antisera against α-synuclein and either SOM (A & B), 
TH (C & D), VAChT (E & F) or VIP (G & H). Varicosities that contained immunoreactivity for α-
synuclein and the other marker are indicated by arrows, and varicosities immunoreactive for either 
α-synuclein or the other marker alone are indicated by arrowheads. Scale bars = 20 μm. 
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Abbreviations: SOM, somatostatin; TH, tyrosine hydroxylase; VAChT, vesicular acetylcholine 
transporter; VIP, vasoactive intestinal polypeptide.  
 
Figure 7. A plot of the mean percentage of α-synuclein-IR varicosities in an 
immunohistochemically-defined population of varicosities against the mean percentage of VAChT-
IR varicosities in the same immunohistochemically-defined population. Plot generated from data in 
Table 3. Abbreviations: -IR, -immunoreactive; 5-HT, 5-hydroxytryptamine; CGRP, calcitonin 
gene-related peptide; NOS, nitric oxide synthase;  SOM, somatostatin; SP, substance P; TH, 
tyrosine hydroxylase; VAChT, vesicular acetylcholine transporter; VIP, vasoactive intestinal 
polypeptide 
 
Figure 8. Matched fluorescence images of guinea-pig rectal myenteric ganglia 
immunohistochemically triple-labeled with antisera against α-synuclein, VAChT and another 
marker. A, B & C: Four different populations of varicosities immunoreactive for SP were 
identified. There were varicosities immunoreactive for SP, VAChT and α-synuclein (indicated by 
arrows). Rarely did varicosities contain immunoreactivity for SP and VAChT without α-synuclein, 
or SP and α-synuclein without VAChT (not shown). Often, varicosities were immunoreactive for 
SP and not VAChT or α-synuclein (indicated by arrow heads). The majority of varicosities 
immunoreactive for VAChT and α-synuclein were not immunoreactive for SP. Populations of 
varicosities immunoreactive for SOM (D, E & F) and VIP (G, H & I) existed in very similar 
proportions to those immunoreactive for SP. Scale bars = 20 μm. Abbreviations: SOM, 
somatostatin; SP, substance P; VAChT, vesicular acetylcholine transporter; VIP, vasoactive 
intestinal polypeptide. 
 
Figure 9. Pie charts showing the immunohistochemically-identified populations of varicosities that 
were immunoreactive for SP and VIP in myenteric ganglia. The size of each population is an 
average of the proportion of immunohistochemically labeled varicosities counted in preparations 
from 4 animals. Abbreviations: +, immunoreactive for the marker; -, lacked immunoreactivity for 
the marker α-Syn, α-Synuclein; SP, substance P; VAChT, vesicular acetylcholine transporter; VIP, 
vasoactive intestinal polypeptide.  
 
Figure 10. Paired fluorescence images of guinea-pig rectal myenteric ganglia containing 
biotinamide-labeled extrinsic axons labeled with antisera against VAChT and α-synuclein. Arrows 
indicate biotinamide-labeled varicosities that were immunoreactive for VAChT and α-synuclein. 
Biotinamide-labeled varicosities belonging to this population were rare. Most biotinamide-labeled 
varicosities were lacked detectable immunoreactivity for VAChT or α-synuclein (indicated by 
arrowheads). Scale bars = 20 μm. Abbreviations: VAChT, vesicular acetylcholine transporter. 
 
Figure 11. Fluorescence and confocal images showing immunohistochemical labeling of myenteric 
ganglia with antisera against a marker. Fluorescence microscopy was used to capture a micrograph 
of a single myenteric ganglion (A, C, E & G). A Z-series of the same myenteric ganglion was then 
captured with a confocal microscope and displayed as a max projection (B, D, F & H). Note the 
density of VAChT-IR and α-synuclein-IR varicosities is much greater in Z-series (B & D) captured 
with a confocal microscope than suggested by a micrograph captured with a fluorescence 
microscope (F & H). Scale bars = 20 μm. Abbreviations: -IR, -immunoreactive; VAChT, vesicular 
acetylcholine transporter.  











